title: Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.
abstract: BACKGROUND
  In order to study the impact on the lung function of patients with cystic fibrosis of the avidity of antipseudomonal antibodies, the avidity of antibodies against the chromosomal beta-lactamase of Pseudomonas aeruginosa (a beta ab) and against the 60-65 kDa heat shock protein of P aeruginosa (anti-GroEL) were measured in serum samples collected longitudinally during chronic infection with P aeruginosa from a group of patients with poor and good lung function.
  
  
  METHODS
  The thiocyanate elution method in which the molarity of potassium thiocyanate required to elute 50% bound antibody under conditions of antigen excess in ELISA was used to measure the relative avidity.
  
  
  RESULTS
  All patients developed increasing levels of a beta ab and anti-GroEL antibodies during the follow up period but no maturation of the avidity of these antibodies was observed. In patients with good lung function the avidity of a beta ab was higher than in patients with poor lung function (p = 0.018). No significant difference in the avidity of the anti-GroEL antibodies was observed between the two groups of patients.
  
  
  CONCLUSIONS
  In patients with cystic fibrosis a high avidity of a beta ab could contribute to a more efficient inhibition of the beta-lactamase by these antibodies, resulting in the better lung function seen in this group. The immunopathological implication of the failure in avidity maturation of antibodies in chronic infection is discussed.
mesh_terms: D000907:Antibodies, Bacterial / Q000276:immunology*; D000915:Antibody Affinity; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000276:immunology* / Q000382:microbiology / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005541:Forced Expiratory Volume / Q000502:physiology; D006360:Heat-Shock Proteins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D011552:Pseudomonas Infections / Q000276:immunology / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D014797:Vital Capacity / Q000502:physiology